Drugs / TILREKIMIG
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06675188 | Jan → Jul 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05411588 | Jun 2022 → May 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06977581 | May 2025 → Mar 2027 expected | asthma | Pfizer | Recruiting | No outcome recorded |
| Phase 2 | NCT05995964 | Aug 2023 → Oct 2026 expected | atopic eczema | Pfizer | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07363694 | Feb 2026 → Oct 2030 expected | chronic obstructive pulmonary disease | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Pfizer | Results Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis pfizer.com ↗
The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥ 75% reduction in the Eczema Area and Severity Index) at Week 16, compared to placebo. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Pfizer | Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis pfizer.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TILREKIMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068474 ↗ |
| Known as | PF-07275315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06675188 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068474 ↗ |
| Route | Intravenous | “SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07275315” NCT05411588 ↗ |
| Route | Subcutaneous | “SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07275315” NCT05411588 ↗ |